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Introduction
Breast cancer is the most commonly diagnosed cancer in women. Approximately 60% to 75% of breast cancers are estrogen receptor alpha positive (ERα + ) (Barnes, 2004) and depend on estrogen for their proliferation (Miller et al., 2008) . In postmenopausal women who do not produce ovarian estrogen, conversion of adrenal androgens to estrogens in peripheral tissues and/or locally in breast tissue by aromatase is a key driver of ERα + breast cancer cell growth (Yue et al., 1998; Chetrite et al., 2000; Simpson et al., 2002) . Aromatase inhibitors (AI) are indicated for these patients as first or second line therapies (Goss, 2003) .
Exemestane is a steroidal (type I) aromatase inhibitor that is structurally related to the natural aromatase substrate 4-androstenedione. It is a mechanism based inactivator that binds irreversibly to the active site of aromatase. Postmenopausal patients with early stage ERα + breast cancer typically receive two to three years of tamoxifen followed by two-three years of exemestane for a total of five years of hormonal therapy (Coombes et al., 2004; van de Velde et al., 2011) . This regimen has been shown to improve relapse-free survival over continuing tamoxifen therapy (Miller et al., 2008; van de Velde et al., 2011) . Exemestane may also be used as primary therapy for early stage invasive breast cancer (Ruddock and Molinari, 2006; Miller et al., 2008) , and for advanced metastatic breast cancer that has progressed following tamoxifen therapy (Lonning and Geisler, 2008; Walker et al., 2013) .
Exemestane is converted into an active metabolite 17-hydroexemestane (17-HE), which has comparable anti-aromatase activity to exemestane (Kamdem et al., 2011) . In addition to binding to aromatase, 17-HE binds weakly to ERα and with moderate/high affinity to the androgen receptor (AR). The majority (67-88%) of ERα + breast cancers express the AR (Moinfar et al., 2003; Hu et al., 2011; Loibl et al., 2011) . 17-HE was reported to induce proliferation and gene activation at micromolar concentrations through ER in both MCF7 and T47D breast cancer cell lines, and via AR at low nanomolar concentrations JPET #240317 7 selectively in T47D cells (Ariazi et al., 2007) . It has been suggested that circulating levels of 17-HE (representing approximately 10% of the parent compound in serum (Evans et al., 1992) ) may be sufficient to regulate AR-dependent activities that decrease bone density loss (Ariazi et al., 2007) . Moreover, 17-HE is reported to inhibit breast cancer cell survival by mechanisms different from those of exemestane (Amaral et al., 2015) ; it is possible that this involves AR-agonism.
UDP-glucuronosyltransferases (UGTs) constitute an enzyme superfamily responsible for the glucuronidation and inactivation of numerous therapeutic drugs and endobiotics including steroid hormones. The major exemestane metabolite found in human urine is the inactive glucuronide of 17-HE. In vitro studies demonstrate that UGT1A4, 2B17, 1A8 and 1A10 are all able to glucuronidate 17-HE, with UGT2B17 showing the highest activity (Sun et al., 2010) . Supporting the primary role of UGT2B17 in exemestane metabolism, UGT2B17 expression levels correlate strongly with 17-HE-glucuronide production in liver microsomes (Sun et al., 2010) . Moreover, patients with the UGT2B17 null genotype showed lower levels of 17-HE-glucuronide in plasma (Chen et al., 2016) . UGT1A4 and UGT2B17 are abundant in liver while UGT1A8 and UGT1A10 are predominantly expressed in the gastrointestinal tract.
UGT2B17, UGT1A8 and UGT1A10 are also expressed at varying levels in normal and cancerous breast tissues (Thibaudeau et al., 2006; Nakamura et al., 2008; Starlard-Davenport et al., 2008; Zhu et al., 2016) and could be involved in intratumoural conjugation of 17-HE. UGT2B17 and its paralog, UGT2B15, conjugate androgens including testosterone and dihydrotestosterone (DHT) (Chen et al., 1993; Beaulieu et al., 1996) . UGT2B17 and UGT2B15 are widely expressed (Levesque et al., 1997; Tchernof et al., 1999; Nakamura et al., 2008; Ohno and Nakajin, 2009; Jones and Lazarus, 2014) including in sex hormonesensitive tissues suggesting roles in maintaining intratissular hormone homeostasis. Indeed, UGT2B17 and UGT2B15 expression and function are linked to the risk of developing JPET #240317 8 androgen-sensitive prostate diseases Gauthier-Landry et al., 2015) . We recently showed that high intratumoural UGT2B17 and UGT2B15 expression levels correlate with better survival outcomes in distinct genetic subgroups of breast cancer (Hu et al., 2016) although how this relates to altered intratumoural steroid metabolism remains to be determined.
We previously defined a conserved 282 bp region of the UGT2B17 and UGT2B15 proximal promoters as an estrogen response unit (ERU) that binds to ERα and mediates induction by estrogens in a FOXA1-dependent manner (Hu and Mackenzie, 2009 ). More recently we determined that the ERU can mediate both estrogenic and androgenic responses in breast cancer cells via binding to both ERα and AR in a FOXA1-dependent manner (Hu et al., 2016) . In the present study, we demonstrate that both exemestane and 17-HE upregulate UGT2B17 and UGT2B15 expression in breast cancer cells. Analysis of the UGT2B17 promoter indicates that induction by exemestane/17-HE is mediated by recruitment of AR to the ERU. We propose that induction of UGT2B17 could facilitate intratumoural inactivation of 17-HE; moreover, induction of both UGT2B17 and UGT2B15 could alter tumour intracrinology, possibly impacting on cancer progression.
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Materials and Methods
Chemicals
Analytical grade chemicals including exemestane (EXE), bicalutamide (BIC), fluvestrant (FUL) were purchased from Sigma-Aldrich (St. Louis, MO).
17-Hydroexemestane (17β-hydroxy-6-methyleneandrosta-1,4dien-3-one) was purchased from hours. Total RNA was isolated using TRIzol reagent (Life Technologies) and reverse transcribed using reagents from Invitrogen (Mulgrave, VIC, Australia) as previously described (Hu and Mackenzie, 2009) . Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) was performed using the RotorGene 3000 (Corbett Research, NSW, Australia), and GoTaq qPCR master mix (Promega, Madison, WI). Sequences of PCR primers that amplify 18S rRNA, UGT1A4, UGT1A8, UGT1A10, UGT2B15, UGT2B17, and GAPDH were reported previously (Hu and Mackenzie, 2009; . Data was analysed using the delta-delta cycle threshold method (Livak and Schmittgen, 2001 ), mRNA levels of target genes were normalized to the levels of 18S rRNA in the same sample and the fold change in mRNA levels after drug treatment was presented relative to levels in vehicletreated cells (set as a value of 1). All treatments were performed in triplicate.
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Western Blotting
Twenty micrograms of total protein from each sample was separated in 10% SDS- Abcam, MA) followed by horseradish peroxidase-conjugated donkey anti-rabbit secondary antibody (Neomarker; Fremont, CA). The same membranes were re-probed with GAPDH antibody (Sigma Aldrich) followed by secondary antibody as mentioned above.
Immunosignals were detected with the SuperSignalWest Pico Chemiluminescent kit (Thermo-Fisher Scientific, Waltham, MA) and an ImageQuant LAS 4000 luminescent image analyzer (GE Healthcare, Chalfont St. Giles, United Kingdom). Quantitation of band intensity and background subtraction was performed using MultiGuge version 3.0 (Fujifilm Corporation, Tokyo, Japan) as described previously (Chanawong et al., 2015) .
Transient transfection and Luciferase Reporter Assay.
This article has not been copyedited and formatted. The final version may differ from this version. Two wild-type UGT2B17 proximal promoter-pGL3 luciferase reporter constructs containing nucleotides -2 to -694 of UGT2B17 and bearing either the common 'A' allele or the rarer 'G' allele within the polymorphic FOXA1 motif were described previously . The cloned promoter region contains one FOXA1 binding site, two estrogen response element (ERE) half sites, and one imperfect ERE site. The previously reported FOXA1 mutated 2B17-694/-2 promoter-reporter construct was also used in this study . As shown in Fig. 6A , this study generated seven additional mutated 2B17-694/-2 constructs using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA), including mutation of a single ERE site [2B17 Mt-3'ERE half-site (2B17 Mt-S1-ERE), 2B17
Mt-5'ERE half-site (2B17 Mt-S2-ERE), and 2B17 Mt-Imperfect ERE (2B17 Mt-S3-ERE)],
, and mutation of three ERE sites simultaneously [2B17 Mt-3'ERE half-site, 5'ERE half-site and Imperfect ERE site (2B17 Mt-T1)]. The sequences of the wildtype and mutated ERE motifs are shown in Table 1 (motifs are underlined and boldfaced). The sequences of the all promoter-reporter constructs were confirmed by DNA sequencing.
MCF-7 cells were seeded into 96-well plates at a density of 3 x 10 4 cells/well in phenol red-free RPMI supplemented with 5% DCC-FBS. After culture overnight, cells were transfected with 100 ng of wild-type or mutated promoter-reporter constructs combined with 2 ng of the control pRL-null (Renilla) vector using 0.4 ul of Lipofectamine 2000 (Invitrogen).
Six hours post transfection, transfection medium was replaced with fresh medium containing 100 nM EXE, 10 nM 17-HE, or vehicle (0.1% DMSO). Cells were harvested after 48 hours in passive lysis buffer and firefly luciferase and Renilla luciferase activities analysed using the Dual-Glo Luciferase Reporter Assay System (Promega, Madison, WI) as described JPET #240317 13 previously . Firefly activities were normalized to Renilla activities, and then the activity of each promoter-reporter construct was normalized to that of the empty pGL3 basic vector within each treatment group. Fold induction of promoter activities after drug-treatment was calculated by normalization to the vehicle-treatment for each promoterreporter construct.
Statistical Analysis
Statistical analysis was performed using one-way or two-way analysis of variance followed by Tukey's posthoc test as indicated in the figures legends. A p-value ≤ 0.05 was considered to be statistically significant.
This article has not been copyedited and formatted. The final version may differ from this version. having the highest catalytic activity (Sun et al., 2010 ) ( Figure 1A ). UGTs are frequently induced by molecules that they metabolize as part of a regulatory feedback loop; hence we considered the possibility that some of these UGTs might also be induced by exemestane. To test this hypothesis, MCF-7 cells maintained in either standard media ( Figure 1B ) or steroidreduced media ( Figure 1C ) were treated with exemestane (100 nM), and mRNA levels of the four UGTs responsible for exemestane-17-O-glucuronide formation, UGT2B17, UGT1A4, UGT1A8, and UGT1A10, were assessed. Exemestane significantly increased the level of UGT2B17 mRNA but not that of UGT1A4, UGT1A8 and UGT1A10 (Figure 1 ). Interestingly we recently showed that UGT2B17, which in addition to liver is expressed in steroid responsive tissues and tumours, is induced by both estrogenic and androgenic signalling cascades in breast cancer cells (Hu et al., 2016) . In contrast, the other UGTs discussed here have not shown significant induction by steroid signalling in previous work. The active exemestane metabolite 17-HE can act as both a weak estrogenic and strong androgenic ligand, suggesting that this metabolite might induce UGT2B17 via either ER or AR signalling.
To begin to assess whether the estrogenic or androgenic function of the exemestane metabolite 17-HE might be responsible for induction of UGT2B17, we treated both Consistent with this interpretation, knock-down of AR with siRNA ( Figure 4C ) led to almost complete inhibition of exemestane and 17-HE mediated induction of UGT2B17 mRNA ( Figure 4D ).
Our recent work showed a critical role for FOXA1 in the induction of UGT2B17 by estrogenic and androgenic ligands (estradiol, tamoxifen, dihydrotestosterone, enobosarm) (Hu et al., 2016) , hence we examined whether FOXA1 may play a role in induction of UGT2B17 by exemestane/17-HE. FOXA1 siRNA dramatically reduced but did not abolish induction of UGT2B17 by both drugs ( Figure 5B ); the residual activation may be due to incomplete inhibition of FOXA1 expression ( Figure 5A ).
To define the region of the UGT2B17 promoter that is involved in induction by exemestane/17-HE, we used UGT2B17 promoter-reporter constructs containing 694 bp of the proximal promoter including the previously defined ERU (Hu et al., 2016) . Mutated (Mt)
reporter constructs were used that contain deletions in the FOXA1 binding motif and the three ER/AR binding motifs (imperfect ERE, 5' ERE half-site, 3' ERE-half site) ( Figure 6A ).
In addition, we used a UGT2B17 promoter construct that contains a naturally occurring SNP in the FOXA1 motif that is referred to as the 'G' allele (the most common allele has an 'A' residue at this position). Previous work showed that the presence of the 'G' residue in the motif reduced binding of FOXA1 . The wild-type promoter construct was Our previous work showed that UGT2B17 and UGT2B15 are regulated similarly by estrogens and androgens via the highly conserved ERU (Hu et al., 2016) . To assess whether exemestane and 17-HE also induce UGT2B15 and whether the mechanism may be the same for UGT2B15 and UGT2B17, we treated MCF-7 ( Figure 7A ) and MDA-MB-453 ( Figure 7B ) breast cancer cells with exemestane (100 nM) or 17-HE (10 nM), with or without BIC or FUL. UGT2B15 mRNA expression was induced by both drugs and this was suppressed by BIC, but not FUL ( Figure 7C ). Similarly, siRNA targeting AR (siAR) but not siRNA targeting ERα (si-ERα) inhibited induction ( Figure 7D ). siRNA targeting FOXA1 also inhibited induction by EXE and 17-HE, suggesting that induction of UGT2B17 and UGT2B15 by these drugs involves very similar molecular mechanisms.
This article has not been copyedited and formatted. The final version may differ from this version. unit in the proximal promoters of both genes that we named the ERU (Hu and Mackenzie, 2009; Hu et al., 2016 ). In the current study, we found that UGT2B17 (and UGT2B15) could be induced by exemestane and its active metabolite, 17-HE. Consistent with the previous observation that 17-HE could act as an AR agonist with high nanomolar affinity, 17-HE induced these genes specifically through the AR. The affinity of exemestane for AR (measured by competitive binding assays) is approximately 100-fold lower than that of 17-HE (Ariazi et al., 2007) ; hence the ability of exemestane to potently induce UGT2B17/UGT2B15 at only 10-fold higher concentration than 17-HE, suggests that it is at least partially converted to 17-HE within the breast cancer cell lines. 17-HE is known to be formed in liver predominantly by CYP1A1/2 (Kamdem et al., 2011) and aldo-keto reductases (AKRs) (Sun et al., 2011) . The conversion of exemestane to 17-HE is likely to also occur in breast tissue and breast cancer cell lines where these enzymes are expressed (Goth-Goldstein et al., 2000; Penning and Byrns, 2009; Rodriguez and Potter, 2013; Yin et al., 2014) . The relative roles of CYP and AKR enzymes in the production of 17-HE in the breast cancer cell lines used in this study is a subject for further investigation.
The UGT2B17/UGT2B15 ERU contains three ERE-like motifs that we previously named the imperfect ERE, 5' ERE half site, and 3' ERE half site, as well as a FOXA1 binding site. We previously showed that the FOXA1 motif was important for AR activity (Hu et al., 2016) and that the 'G' allele SNP in the FOXA1 motif impaired FOXA1 binding. suggest that individuals homozygous for the 'G' allele may not induce UGT2B17 in response to exemestane; however the therapeutic consequence of this, if any, will require further study as discussed below.
In recent work we used high resolution ChIP analysis and mutational analysis of the UGT2B15 promoter in MCF7 cells to show that the imperfect ERE may bind predominantly to ER, whereas the 3' ERE might be the predominant binding site for AR (Hu et al., 2016) .
These previous studies used DHT and the selective androgen receptor modulator (SARM) enobosarm as AR ligands. In contrast, in the current study, mutational analysis of the UGT2B17 promoter in MCF7 cells suggested that all three ERE-like motifs may play equal and additive roles in the response to 17-HE-liganded AR. Moreover, the motifs are at least partially redundant, as deletion of all three motifs was required to completely eliminate the response to these drugs.
It is also notable that in our previous study, induction of UGT2B15 mRNA by DHT We recently showed that UGT2B15 can be induced by tamoxifen and its active metabolite 4-OH tamoxifen via the ERU (Chanawong et al., 2015) . Because UGT2B15
glucuronidates and inactivates 4-OH-tamoxifen, its intratumoural induction by tamoxifen generates a potential regulatory feedback loop that might impact on therapeutic efficacy and promote the acquisition of drug resistance (Chanawong et al., 2015) . The ability of UGT2B17
to conjugate 17-HE suggests the possibility of a similar regulatory feedback loop in which exemestane/17-HE-mediated induction of UGT2B17 increases local inactivation of 17-HE.
However, the relevance of this feedback loop to exemestane efficacy in vivo depends upon whether aromatase and UGT2B17 are co-expressed. In situ aromatization of androgens is an important mechanism for promoting growth of ER + breast cancer. While this is considered primarily a paracrine effect with aromatase expressed in breast stromal fibroblasts and preadipocytes/adipocytes (Zhou et al., 2001; Catalano et al., 2014; Wang et al., 2015) , there is also evidence for aromatase expression in some carcinoma cells within invasive ductal carcinoma as well as in some breast cancer cell lines (Chetrite et al., 2000; Rajhans et al., 2008; Sasano et al., 2009; McNamara and Sasano, 2015; Takagi et al., 2016) . Moreover, coculture of MCF7 cells with breast cancer stromal cells was able to induce aromatase expression in the former. (Sasano et al., 2009) . Hence a small subset of tumours may have functionally relevant autocrine ER signalling mediated by aromatization within carcinoma cells, in addition to stromal estrogen synthesis. In such tumours, induction of UGT2B17 by exemestane/17-HE in carcinoma cells might lead to reduction in exemestane efficacy.
It is also possible that UGT2B17 is expressed in breast tumour stromal tissue, and this requires further investigation. In support of the latter idea, UGT2B17 was found to be highly expressed in stromal fibroblasts of normal prostate (Barbier et al., 2000) . Of note, AR is also expressed in breast cancer stromal cells (Lanzino et al., 2016) . To date studies of exemestane metabolism in breast cancer patients with the UGT2B17 null genotype (~12% of the population) have been restricted to measuring altered levels of 17-HE-glucuronide in plasma (Chen et al., 2016) . The effect of the UGT2B17 null genotype (and indeed the effect of UGT2B17-FOXA1 motif polymorphism) on intratumoural drug levels, and whether this may impact on exemestane efficacy, remains to be examined.
The role of androgens in ERα + /AR + breast cancer remains poorly defined, although AR expression has been associated with reduced mortality (Castellano et al., 2010; Hu et al., 2011) , and androgens may antagonize estrogenic signalling by a variety of mechanisms (Hickey et al., 2012) . In contrast, in ERα -/AR + breast cancers, or those in which ERα has been functionally ablated by long term anti-estrogen therapy, androgen signalling may be pro-proliferative (Cochrane et al., 2014; Barton et al., 2015; Zhu et al., 2016) . Aromatase activity reduces local and circulating androgen levels by conversion to estrogens; exemestane has been shown to significantly increase intratumoural levels of DHT in vivo (Takagi et al., 2010) . Exemestane also increases expression of 17-hydroxysteroid dehydrogenase (HSD)2 that converts estradiol to the weak estrogen estrone, hence further reducing estrogenic signalling (Takagi et al., 2010) . The combined effect of the increase in DHT, decrease in estrogen synthesis, and increased conversion of estradiol to estrone, may all contribute to reduced breast cancer growth through lowering the estradiol:DHT ratio (Takagi et al., 2010) .
As DHT and testosterone are primarily inactivated by UGT2B17 and UGT2B15 (Chouinard et al., 2008) , the induction of these UGTs by exemestane/17-HE could have an anti-androgenic effect in breast cancer cells. In particular, a reduction in DHT levels due to independent experiments performed in triplicate. Statistical significance was assessed using one-way ANOVA followed by Tukey's post hoc test. p-value ≤ 0.05, **p-value ≤ 0.01, ***pvalue ≤ 0.001, ****p-value ≤ 0.0001). 
